

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: PANGENOMIC HEALTH INC. (the "Issuer").

Trading Symbol: NARA

Number of Outstanding Listed Securities: 72,695,972 common shares

Date: December 1, 2022

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. **Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

PanGenomic Health Inc. is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. Our initial focus is on mental health. As a British Columbia benefit company, the Issuer's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.

During the month of November 2022, the Issuer continued with its general and corporate activities of the business.

2. Provide a general overview and discussion of the activities of management.

During the month of November 2022, the Issuer continued overseeing corporate activities, which included continued development and marketing of the Nara consumer app and PlantGx clinical decision support platform.

On November 21, 2022, the Issuer announced by the way of news release that, further to its news release dated September 1, 2022, it has entered into a definitive share exchange agreement dated November 18, 2022 (the "Share Exchange Agreement") with Mydecine Innovations Group Inc. ("Mydecine"), a company listed on the NEO Exchange (the "NEO"), and Mydecine's wholly owned subsidiary, Mindleap Health Inc. ("Mindleap"), to acquire all of the issued and outstanding shares of Mindleap (the "Transaction"). Mindleap launched the world's first telehealth platform for psychedelic integration on the iOS and Android stores in 2020.

Proposed Acquisition of Mindleap

Pursuant to the Share Exchange Agreement, the Company will acquire all of Mindleap's outstanding shares for a purchase price of C\$3,600,000 (the "Purchase Price"), payable by the issuance of units (each a "Unit") of the Company at a price of C\$0.20, or such greater price as may be required by the Canadian Securities Exchange ("CSE"), per Unit (the "Unit Price"). Each Unit will be comprised of one Class A Common Share of PanGenomic (a "Common Share") and one share purchase warrant (each a "Unit Warrant") to purchase one additional Common Share (a "Unit Warrant Share") at a price of C\$0.30, or such greater price as may be required by the CSE, per Unit Warrant Share for 24 months from the closing of the Transaction (the "Closing"). Closing is subject to a number of customary conditions, including the approval of the CSE and the NEO, if required under the rules and policies of the CSE and the NEO.

Upon Closing and in support of the proposed Transaction, the Company and Mydecine are expected to enter into a transition services agreement whereby the Company will engage Mydecine to assist in the transition, transfer, and integration of Mindleap's technologies into PanGenomic's technology platform (the "Services") for two months following the Closing. In return for the Services, the Company shall pay to Mydecine a monthly consulting fee of C\$50,000 (C\$100,000 total), payable at the Closing and on the one-month anniversary of the Closing. In addition, in connection with the proposed Transaction, the Company has entered into a fee agreement with two third party consultants for introductory and advisory services provided to the Company, including identifying and assisting in the evaluation of the proposed Transaction and introducing the Company to Mydecine and Mindleap. The Company agreed to pay the consultants an aggregate fee of C\$400,000 upon Closing, to be paid by the issuance of Units to the consultants at the Unit Price.

Upon Closing, Mindleap is expected to be operated as a wholly-owned subsidiary of the Company and to focus on B2C and B2B services for the psychedelic-assisted therapy industry. Upon Closing, Mydecine is expected to hold approximately 19.4% of the issued and outstanding Common Shares. No changes to the management or board of directors of the Company are required or expected to be made as a result of the Transaction.

In addition, management of the Issuer spent significant time preparing and filing its financial statements, management's discussion and analysis and related certifications for the nine-month period ended September 30, 2022 (the "**Financial Report**").

The Issuer's aforementioned news release and Financial Report can be viewed under the Issuer's profile on SEDAR (www.sedar.com). The Issuer's aforementioned news release can also be viewed under the Issuer's Disclosure page on the website of the Canadian Securities Exchange.

3. **Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

None to report during the month of November 2022.

4. **Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.**

None to report during the month of November 2022.

5. **Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.**

None to report during the month of November 2022.

6. **Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

None to report during the month of November 2022.

7. **Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.**

None to report during the month of November 2022.

8. **Describe the acquisition of new customers or loss of customers.**

None to report during the month of November 2022.

9. **Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.**

None to report during the month of November 2022.

10. **Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**

During the month of November 2022, the Issuer hired a new marketing employee.

11. **Report on any labour disputes and resolutions of those disputes if applicable.**

None to report during the month of November 2022.

12. **Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

None to report during the month of November 2022.

13. **Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

None to report during the month of November 2022.

14. **Provide details of any securities issued and options or warrants granted.**

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
No securities were issued during the month of November 2022.			

(1) State aggregate proceeds and intended allocation of proceeds.

15. **Provide details of any loans to or by Related Persons.**

None to report during the month of November 2022.

16. **Provide details of any changes in directors, officers or committee members.**

None to report during the month of November 2022.

17. **Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

The trends and risks which are likely to impact the Issuer are detailed in the section named "Risk Factors" of the Issuer's Prospectus dated January 14, 2022, the Issuer Filing Statement dated July 13, 2022 and the Issuer's Management Discussion and Analysis dated November 28, 2022 (the "**MD&A**"), under the heading "Risk and Uncertainties". The Prospectus and Filing Statement can be viewed under the Issuer's Disclosure page on the website of the Canadian Securities Exchange. The MD&A can be viewed under the Issuer's profile on SEDAR (www.sedar.com).

THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: December 1, 2022

Maryam Marissen
Name of Director or Senior Officer

"Maryam Marissen"
Signature

Chief Executive Officer
Official Capacity

Issuer Details	For Month Ended	Date of Report
Name of Issuer PANGENOMIC HEALTH INC.	November 2022	YYYY / MM / DD 2022 / 12 / 01
Issuer Address Suite 102 – 3800 Wesbrook Mall		
City/Province/Postal Code Vancouver, BC V6S 2L9	Issuer Fax No. N/A	Issuer Telephone No. 778-743-4642
Contact Name Maryam Marissen	Contact Position CEO	Contact Telephone No. 778-743-4642
Contact Email Address maryam@pangenomic.com	Web Site Address www.pangenomic.com	